Further, given that in stroke patients, the number of circulating Tregs decreases dramatically post-stroke (Urra et al., 2009), investigating whether Tregs and the regulatory factors produced, such as IL-10 or TGF-β, ameliorate resultant neuroinflammation/neurodegeneration after TBI is clearly warranted (Jassam et al., 2017). This evidence concerns the gene TGFB1 and stroke disorder.